Supreme Court arguments on Tuesday, regarding the legality of federal regulations allowing the distribution of the abortion drug mifepristone through the mail, hinged on whether the anti-abortion doctors association that brought the case had standing to sue in the first place.
The case, known as FDA v. Alliance for Hippocratic Medicine and combined with a similar case, centers on whether the Food and Drug Administration overlooked health and safety issues when it loosened restrictions around mifepristone, one of the two drugs used in medication abortion, in 2016 and 2021. The FDA approved mifepristone in 2000, and the medication has since been used by nearly 6 million people in the U.S., according to the department.
